Drug Profile
Ipilimumab biosimilar - CStone Pharmaceuticals
Alternative Names: CS-1002Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator CStone Pharmaceuticals
- Class Antineoplastics; Antiretrovirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in China (IV)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Australia (IV)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Hong Kong (IV)